Anavex as a New Aspirin
My posting here of this personal perspective diminishes (for some, anyway) my more evidence-based, substantive postings. Nonetheless, I’ll set it out.
I would so much wish to see a murine (rats) study of chronic administration of Anavex 3-71, to determine its effects on the onset and severity of aging. (A3-71 appears to be better than A2-73.)
Inasmuch as disrupted cellular homeostasis (normal cell functioning) is involved with virtually all neurodegenerative diseases (Alzheimer’s, Parkinson’s, ALS, et al. ), chronic administration of A3-71 has the potential of preventing or retarding the onset of any of these, if administered before any symptoms appear. Similar cellular dysfunctions amenable to Anavex therapies may be revealed in other major disease complexes, including diabetes, cardiovascular conditions, and psychiatric debilities (there already is preliminary lab animal evidence for efficacies in each of these).
So infrequently mentioned in discussions of Anavex drugs is their profound tolerability, the absence of any severe adverse effects. Simply put, Anavex 2-73 in the recent human trial simply had no disqualifying severe adverse effects; just a few, very minor side effects; which may well have been coincidental with other conditions, or normal disease state variabilities. For drugs affecting nerves and the nervous system, this is virtually unheard of.
The safety of Anavex 2-73 (and equally, A3-71, to be demonstrated more completely in new murine and human studies) is profound. Game-changing.
What if (as I expect) expanded human trials of either of these drugs reveals no adverse effects, in the manner of, say, aspirin? Yes, aspirin can cause intestinal bleeding and minor blood loss. But its benefits far out weigh those minor (well, sometimes more considerable) side effects.
As I’ve mentioned before, the prospect of every 40- or 50-year old popping a prophylactic (disease preventing) Anavex pill each morning at breakfast is not at all eventually out of the question — with profound chronic health benefits. An anti-aging therapy, as it were.
Try it first on 100 rats, fifty getting glucose in their water drips, and 50 getting some Anavex 3-71. Simply record the course of their diseases as they age, along with a quantification of any side effects. As with humans, the frequency and incidence of geriatric conditions in aging rats is well-known. They get old and diseased and mentally reduced as do we with age. I’m betting that one or two of the Anavex molecules will prevent or retard the onset of old-age symptoms in rats — then, in humans.
Ponder the social and fiscal implications, should this be so.
